Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 3
2007 2
2008 9
2009 8
2010 9
2011 10
2012 1
2013 8
2014 13
2015 13
2016 15
2017 13
2018 6
2019 13
2020 8
2021 11
2022 12
2023 13
2024 23
2025 25
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
A first-in-class EGFR-directed KRAS G12V selective inhibitor.
Stanland LJ, Huggins HP, Sahoo SS, Porrello A, Chareddy Y, Azam SH, Perry JL, Pallan PS, Whately K, Edatt L, Green WD, Fleming MC, Im J, Gutierrez-Ford C, Simmons I, Dawoud A, Zhou KI, Jayaprakash V, Sellers RS, Cruz G, Wielgus A, Milner J, Egli M, Bowers AA, Pecot CV. Stanland LJ, et al. Among authors: jayaprakash v. Cancer Cell. 2025 Oct 13;43(10):1815-1832.e10. doi: 10.1016/j.ccell.2025.05.016. Epub 2025 Jun 19. Cancer Cell. 2025. PMID: 40541192 Free article.
Somatostatinoma.
Jayaprakash V, Menon G. Jayaprakash V, et al. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 31869077 Free Books & Documents.
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Ferris RL, et al. Among authors: jayaprakash v. Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17. Oral Oncol. 2018. PMID: 29884413 Free PMC article. Clinical Trial.
2-[(4,6-Di-amino-pyrimidin-2-yl)sulfan-yl]-N-(2-methyl-phen-yl)acetamide.
Subasri S, Kumar TA, Sinha BN, Jayaprakash V, Velmurugan D. Subasri S, et al. Among authors: jayaprakash v. Acta Crystallogr Sect E Struct Rep Online. 2014 Jul 5;70(Pt 8):o850. doi: 10.1107/S1600536814015256. eCollection 2014 Aug 1. Acta Crystallogr Sect E Struct Rep Online. 2014. PMID: 25249901 Free PMC article.
A new potent and selective peroxisome proliferator-activated receptor alpha partial agonist displays anti-steatotic effects In vitro and behaves as a safe hypolipidemic and hypoglycemic agent in a diabetic mouse model.
Laghezza A, Falbo E, Gilardi F, Thomas A, Brunetti L, Leuci R, Piemontese L, Tortorella P, Biswas A, Singh RP, Pattnaik AK, Jayaprakash V, Tambe S, Ca S, Wackerlig-Damle J, Paoli P, Loiodice F, Lavecchia A. Laghezza A, et al. Among authors: jayaprakash v. Eur J Med Chem. 2025 May 5;289:117494. doi: 10.1016/j.ejmech.2025.117494. Epub 2025 Mar 11. Eur J Med Chem. 2025. PMID: 40088662 Free article.
190 results